Wall Street analysts expect that OraSure Technologies, Inc. (NASDAQ:OSUR) will report earnings of $0.07 per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for OraSure Technologies’ earnings. OraSure Technologies posted earnings of $0.20 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 65%. The business is expected to report its next quarterly earnings report after the market closes on Wednesday, February 19th.
On average, analysts expect that OraSure Technologies will report full year earnings of $0.30 per share for the current fiscal year. For the next financial year, analysts forecast that the business will report earnings of $0.24 per share, with EPS estimates ranging from $0.18 to $0.30. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow OraSure Technologies.
Several equities analysts have issued reports on OSUR shares. Zacks Investment Research raised shares of OraSure Technologies from a “sell” rating to a “hold” rating in a report on Wednesday, December 11th. ValuEngine raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, January 7th. BidaskClub lowered shares of OraSure Technologies from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 29th. Finally, Canaccord Genuity reaffirmed a “hold” rating and issued a $8.00 price target on shares of OraSure Technologies in a report on Monday, November 11th.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lenox Wealth Advisors LLC grew its holdings in OraSure Technologies by 2,395.3% in the fourth quarter. Lenox Wealth Advisors LLC now owns 3,219 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 3,090 shares during the last quarter. Parallel Advisors LLC acquired a new stake in shares of OraSure Technologies during the fourth quarter worth $39,000. Aigen Investment Management LP acquired a new stake in shares of OraSure Technologies during the fourth quarter worth $43,000. Advisor Group Inc. lifted its stake in shares of OraSure Technologies by 423.7% during the fourth quarter. Advisor Group Inc. now owns 7,107 shares of the medical instruments supplier’s stock worth $56,000 after buying an additional 5,750 shares during the period. Finally, Emerald Advisers LLC acquired a new stake in shares of OraSure Technologies during the fourth quarter worth $76,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.
OSUR stock traded up $0.12 during trading on Friday, hitting $6.84. 339,933 shares of the company’s stock traded hands, compared to its average volume of 410,523. The firm has a market capitalization of $412.33 million, a P/E ratio of 17.54, a PEG ratio of 2.23 and a beta of 1.19. The business has a fifty day simple moving average of $7.62 and a two-hundred day simple moving average of $7.75. The company has a quick ratio of 6.85, a current ratio of 7.72 and a debt-to-equity ratio of 0.01. OraSure Technologies has a 1 year low of $6.35 and a 1 year high of $11.87.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Featured Article: Inverted Yield Curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.